Q: Nanotechnology is often hyped as either a miracle cure-all or a potential danger. How much of this is grounded in truth and what is the practical reality of the technology?
Innovative nanoscience in concert with the increased knowledge arising from genomics and proteomics research is creating exciting opportunities for nanomedicine development using advances in materials science and, in some cases, innovative therapeutics such as siRNA and aptamers. There is also real potential to develop novel multicomponent systems (e.g., those involving gold or iron nanoparticles, and polymers and therapeutics as single agents or combination therapies). More in depth discussion about the opportunities and challenges in these areas can be read in a Duncan and Gaspar paper (1).Q: What new therapies can nanotechnology enable?
To answer this question, I advise readers to take a look at an interesting historical overview by B. Munos (2). He explains that during the last 60 years, the FDA has approved approximately 1200 new chemical entities, as well as around 120 biologicals/proteins. Roughly 40 nanomedicine products have also reached the market, which is interesting given the relatively minor investment of pharma companies in this area compared with that for low-molecular weight chemical entities and biotech products.
In the coming years, I believe we will see an increasing number of nanomedicine products. Consider for instance that low-molecular weight synthetic chemotherapy was only born at the beginning of the last century.
In my view, some of the particularly interesting opportunities/advances in nanomedicines include:
Q: How fast (or slow) has the pharma industry been to embrace nanotechnology?
The 40 or so first-generation nanomedicines on the market began to arrive in 1990 and now there are many follow-up products and novel nanotechnology approaches in pipelines. In particular, specific technologies, such as nanocrystals, have been rapidly embraced over the last decade because they can help solve specific formulation challenges, such as poor water solubility.
When all these technologies emerged as first in class, they were, as with any new, high-risk technology, embraced very slowly by pharma companies. However, once a technology has arrived in the market, there is always a sudden burst of interest, particularly as some products gain blockbuster status. With nanotechnology now well established, coupled with the high-drug attrition rate for low-molecular weight chemical entities, interest in this area has certainly increased.